Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 9,418 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetics, Clear all
Terminated Phase 4 Interventional Accepts healthy volunteers

Comparison of PKs of 17-Beta-Estradiol Via Sublingual Placement Versus Swallowing in Male-to-Female Transgender Patients

NCT05428215
View directory record Official record
Conditions
Gender Dysphoria
Interventions
17beta Estradiol
Drug
Lead sponsor
MaineHealth
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia

NCT02780115
View directory record Official record
Conditions
Presbyopia
Interventions
AGN-199201 ophthalmic solution, AGN-190584 ophthalmic solution, AGN-199201 Vehicle, AGN-190584 Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 55 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
25
States / cities
Arcadia, California • Artesia, California • Cypress, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease

NCT03574363
View directory record Official record
Conditions
Chronic Kidney Diseases, Hypertension
Interventions
KBP-5074 0.25 mg tablet, KBP-5074 0.5 mg tablet
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Princeton, New Jersey • Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of ONO-2020 in Healthy Participants

NCT05507515
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ONO-2020, Placebo
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

NCT06723535
View directory record Official record
Conditions
Kidney Failure, Chronic, Healthy Volunteers, Renal Impairment
Interventions
BMS-986278
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 84 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis

NCT03041025
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
GSK2330811, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 2, 2026, 11:23 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Influence of the Gut Microbiome on Blueberry Polyphenol Metabolites

NCT07607158
View directory record Official record
Conditions
Microbiome Analysis, Metabolomics
Interventions
Freeze-dried blueberry powder beverage
Other
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study With a Potential Alzheimer's Disease Compound

NCT00726726
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan), BMS-708163, BMS-708163 + Cooperstown Cocktail
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2008 · Synced Oct 2, 2026, 11:23 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults

NCT07455084
View directory record Official record
Conditions
Schizophrenia
Interventions
14C-SEP-380135
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects

NCT07473752
View directory record Official record
Conditions
Phase 1 First-in-human Study Involving Healthy Subjects
Interventions
TNX-1500, Placebo: USP 0.9% sterile saline for injection, Keyhole Limpet Hemocyanin (KLH)
Drug · Biological
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 2, 2026, 11:23 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

NCT07643155
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Treprostinil Palmitil Inhalation Powder
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
4
States / cities
Lake Forest, California • San Dimas, California • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 2, 2026, 11:23 AM EDT
Recruiting Phase 1 Interventional

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

NCT06983743
View directory record Official record
Conditions
Metastatic Solid Tumors
Interventions
ERAS-0015, ERAS-0015 in combination
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Santa Rosa, California • Aurora, Colorado • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 2, 2026, 11:23 AM EDT
Terminated Phase 1Phase 2 Interventional

Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

NCT00884715
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Octreotide
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Iowa City, Iowa • Boston, Massachusetts • Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

NCT01371825
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency, Wolman Disease
Interventions
Sebelipase alfa (SBC-102)
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 2, 2026, 11:23 AM EDT
Terminated Phase 2 Interventional Results available

A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.

NCT01972776
View directory record Official record
Conditions
COPD
Interventions
QBM076, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)

NCT02402309
View directory record Official record
Conditions
Sjögren-Larsson Syndrome
Interventions
Active topical NS2 1% dermatologic cream, Vehicle placebo 0.0% NS2 dermatologic cream
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Omaha, Nebraska • Hershey, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Food on Evacetrapib (LY2484595) in Healthy Participants

NCT01810432
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Evacetrapib, High-fat Meal
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 1 Interventional

Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy

NCT00001387
View directory record Official record
Conditions
Neoplasms
Interventions
paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pediatric Study to Access Pharmacokinetics and Safety of Oraqix Gel

NCT01591616
View directory record Official record
Conditions
Periodontal Disease
Interventions
lidocaine and prilocaine
Drug
Lead sponsor
Dentsply International
Industry
Eligibility
6 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 2, 2026, 11:23 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome

NCT05127226
View directory record Official record
Conditions
Angelman Syndrome
Interventions
ION582
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
0 Years to 50 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
6
States / cities
San Diego, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 2, 2026, 11:23 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

NCT04431726
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
0 Months to 12 Months
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 1 Interventional

A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

NCT06006585
View directory record Official record
Conditions
Geographic Atrophy
Interventions
BI 771716
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Walnut Creek, California • Jacksonville, Florida • Melbourne, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 2, 2026, 11:23 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment

NCT06740799
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Quizartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Miami, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects

NCT00329147
View directory record Official record
Conditions
Depression
Interventions
desvenlafaxine SR, desipramine, paroxetine
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 7, 2007 · Synced Oct 2, 2026, 11:23 AM EDT